Profile

Jinbiao Zhan,Ph D, Professor  

Director, and Principal Investigator of Lab for Gene & Antibody Engineering.  Estabolished phagy-displayed single-chain antibody library and discoved a number of scFv antibodies against CD33, PD1 and PD-L1 which can be used for antibody -drug development and CAR-T cell immunotherapy.  Key research: Biomaterials 2015, Expert Opin Investig Drugs 2013, Biodrugs 2006,Toxicology 2003, Cancer Immunol immunother 1998.

Recent publications (# in Chinese ):

1. Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan JB. Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Des Devel Ther. 2017;11:2265-2276

2. Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J. Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery.  Immunol Lett. 2017; 190:34-41

3. Li QB, Tang Q, Zhang PZ,Wang ZH, Zhao TT, Zhou JL, Li HR, Ding Q,Li W, Hu FQ, Du YZ, Ruan H, Chen SQ, Gao JQ, Zhan JB*, You J*. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. Biomaterials 2015; 57:1-11

4. Chen J, Ding Q, Chen SQ, Zhan JB.Signaling Pathways of Immune Checkpoint Protein  PD1 and Cancer Immunotherapy. Chinese Journal of Cell Biology 2016,38(11):1433-1440 #

5.  Li HR, Ding Q, Chen SQ, Zhan JB. Antibody Therapeutics that Targets Cancer Stem Cells—for Some Signal Pathways and CSC Markers. Chinese Journal of Cell Biology 2015,37(1):115-123 #

6. Zhang ZZ, Ding Q, Tang Q, Li HR,Zhan JB.  Progress in Antibody-Drug Conjugates Directed against CD33,Chinese Journal of Cell Biology 2014,(01):106-114 #

7. Zhan, JB,Han Q,Wang KY,Development of antibody therapeutics for small cell lung cancer,Expert Opin Invest Drugs 2013,22(2):235-244

8. Ding Q,Zhan JB,Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer,Drug Des Devel Ther. 2013,7:681-689

9. Lin L, Ding Q, Tang Q, Zhang ZZ, Dai Z, Zhan JB,Antibody-drug conjugates and their application in the  treatment of hematological malignancies

Acta Pharmaceutica Sinica 2012,(10):1287-1296  #

10. Tang Q, Ding Q, Lin L, Zhang ZZ, Dai Z, Zhan JB,Development of antibody drugs targeting against HER2 for cancer therapy,Acta Pharmaceutica Sinica,2012,(10):1297-1305 #

11. Zhao TT, Fan NN, Lin L,Ding Q, Zhan JB. Development of therapeutic antibodies for gastric and colorectal cancers. Journal of Zhejiang University( Medical Sciences) , 2012,41(3):347-355 #

12. Fang M, Wang J, Han S, Hu ZY, Zhan JB, Ling SC,Rudd JA, Geng Y. Protective effects of w-conotoxin on Amyloid-β-induced damage in PC12 cells. Toxicol Lett 2011,206(3): 245-346

13. Fan NN, Ding Q, Zhao TT,Zhan JB:Monoclonal antibody drugs for the treatment of hematological malignancies.Chinese Journal of Cell Biology 2011,33(9):1015-1021 #

14. Zhang LL,Ding Q, Zhan JB:Expression of recombinant ribosome-inactivating protein MAP30 in E.coli and its biological activity,Journal of Zhejiang University( Medical Sciences) 2010,39(3):264-271 #

15. Fang M, Wang J, Han S, Hu ZY, Zhan JB, Ling SC, Rudd JA, Geng Y. Protective effects of w-conotoxin on Amyloid-β-induced damage in PC12 cells. Toxicol Lett 2011,206(3): 245-346

16. Fan NN,Ding Q,Zhao TT,Zhan JB. Monoclonal antibody drugs for the treatment of hematological malignancies. Chinese Journal of Cell Biology 2011,33(9):1015-1021#


Research work

Main Research Interests 1.Therapeutic Antibodies, Antibody-drug Conjugates 2.Phagy-displayed Antibody Library 3.Cancer Immunotherapy

Contact

Phone:0571-88208272
E-mail:jzhan2k@zju.edu.cn